Kalvista Pharmaceuticals Inc

KALV

Add to Watchlist

26.755USD

-0.005-0.02%

Market hours （ET）Quotes delayed by 15 min

Kalvista Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

18 / 382

Overall Ranking

104 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Kalvista Pharmaceuticals Inc Highlights

StrengthsRisks

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.

Growing

The company is in a growing phase, with the latest annual income totaling USD 49.08M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 49.08M.

Undervalued

The company’s latest PE is -13.16, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 74.08M shares, increasing 4.22% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 4.07K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 4.74.

Analyst Rating

Based on 7 analysts

Hold

Current Rating

29.875

Target Price

+11.47%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Kalvista Pharmaceuticals Inc is 6.36, ranking 251 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 40.86M, representing a year-over-year increase of 15.48%, while its net profit experienced a year-over-year increase of 147.55%.

Score

Industry at a Glance

Previous score

6.36

Change

0



Financials

8.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.57

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.56

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.53

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.12

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Kalvista Pharmaceuticals Inc is 5.95, ranking 337 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -13.16, which is -89.77% below the recent high of -1.35 and -0.15% above the recent low of -13.18.

Score

Industry at a Glance

Previous score

5.95

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 18/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Kalvista Pharmaceuticals Inc is 8.89, ranking 37 out of 382 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 39.00 and a low of 22.00.

Score

Industry at a Glance

Previous score

6.57

Change

2.32

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Kalvista Pharmaceuticals Inc is 9.77, ranking 2 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 29.52 and the support level at 21.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.79

Change

-0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-14

The current institutional shareholding score of Kalvista Pharmaceuticals Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 139.34%, representing a quarter-over-quarter increase of 11.98%. The largest institutional shareholder is Steven Cohen, holding a total of 2.78M shares, representing 5.23% of shares outstanding, with 3767.18% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

VR Adviser, LLC

6.51M

-3.19%

Frazier Life Sciences Management, L.P.

5.04M

+0.35%

Suvretta Capital Management, LLC

4.77M

--

Tang Capital Management, LLC

4.57M

-9.29%

BlackRock Institutional Trust Company, N.A.

2.98M

+8.89%

Capital World Investors

2.81M

-11.61%

Point72 Asset Management, L.P.

Star Investors

2.78M

+21.81%

SilverArc Capital Management, LLC

2.43M

+78.02%

Emerald Advisers LLC

2.20M

-3.23%

Woodline Partners LP

1.92M

+0.02%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Kalvista Pharmaceuticals Inc is 5.26, ranking 47 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is -0.12. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Kalvista Pharmaceuticals Inc

KALV

7.74 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.66 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment